UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 29

Sortiert nach

Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN

Cancer research (Chicago, Ill.), 2018-06, Vol.78 (12), p.3122-3134

2018

Link zum Volltext

Verfügbarkeit prüfen

Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition

Clinical cancer research, 2016-05, Vol.22 (10), p.2470-2481

2016

Link zum Volltext

Verfügbarkeit prüfen

MiR‐137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A

International journal of cancer, 2013-09, Vol.133 (5), p.1064-1073

2013

Link zum Volltext

Verfügbarkeit prüfen

Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma

International journal of molecular sciences, 2023-11, Vol.24 (21), p.15571

2023

Link zum Volltext

Verfügbarkeit prüfen

MYCN-targeting miRNAs are predominantly downregulated during MYCN‑driven neuroblastoma tumor formation

Oncotarget, 2015-03, Vol.6 (7), p.5204-5216

2015

Link zum Volltext

Verfügbarkeit prüfen

Effective Alu repeat based RT-Qpcr normalization in cancer cell perturbation experiments

PloS one, 2013-08, Vol.8 (8), p.e71776

2013

Link zum Volltext

Verfügbarkeit prüfen

RNA expression signatures and posttranscriptional regulation in diabetic nephropathy

Nephrology, dialysis, transplantation, 2015-08, Vol.30 Suppl 4 (suppl 4), p.iv35-iv42

2015

Link zum Volltext

Verfügbarkeit prüfen

BET bromodomain protein inhibition is a therapeutic option for medulloblastoma

Oncotarget, 2013-11, Vol.4 (11), p.2080-2095

2013

Link zum Volltext

Verfügbarkeit prüfen

miR‐542‐3p exerts tumor suppressive functions in neuroblastoma by downregulating Survivin

International journal of cancer, 2015-03, Vol.136 (6), p.1308-1320

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2481: Time-resolved transcriptome analysis of murine TH-MYCN driven neuroblastoma identifies MEIS2 as early initiating factor and novel core gene regulatory circuitry constituent

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.2481-2481

2021

Link zum Volltext

Verfügbarkeit prüfen

Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time

World journal of urology, 2019-12, Vol.37 (12), p.2557-2564

2019

Link zum Volltext

Verfügbarkeit prüfen

Model-Based Classification for Digital PCR: Your Umbrella for Rain

Analytical chemistry (Washington), 2017-04, Vol.89 (8), p.4461-4467

2017

Link zum Volltext

Verfügbarkeit prüfen

MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma

Cancer letters, 2015-09, Vol.366 (1), p.123-132

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1527: BRD3 as a specific vulnerable therapeutic target in neuroblastoma

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1527-1527

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract LB-051: High LDHA expression predicts decreased survival in neuroblastoma

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.LB-051-LB-051

2017

Link zum Volltext

Verfügbarkeit prüfen

miRBase Tracker: keeping track of microRNA annotation changes

Database : the journal of biological databases and curation, 2014, Vol.2014

2014

Link zum Volltext

Verfügbarkeit prüfen

MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma

Oncotarget, 2016-10, Vol.7 (41), p.66344-66359

2016

Link zum Volltext

Verfügbarkeit prüfen

SP248ENDOGENOUS CONTROLS FOR MIRNA ANALYSIS IN RNEAL CELLS AND TISSUE

Nephrology, dialysis, transplantation, 2016-05, Vol.31 (suppl_1), p.i169-i170

2016

Link zum Volltext

Verfügbarkeit prüfen

Targeting tachykinin receptors in neuroblastoma

Oncotarget, 2017-01, Vol.8 (1), p.430-443

2017

Link zum Volltext

Verfügbarkeit prüfen

Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis

Molecular oncology, 2016-06, Vol.10 (6), p.866-878

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3967: BET protein inhibitor OTX015 has selective anti-tumoral activity in preclinical models of MYCN- amplified neuroblastoma

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.3967-3967

2014

Link zum Volltext

Verfügbarkeit prüfen

The mutational landscape of MYCN, Lin28b and ALKF1174L driven murine neuroblastoma mimics human disease

Oncotarget, 2018-02, Vol.9 (9), p.8334-8349

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(29)

Sprache

Englisch
(29)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(19)
Humans
(17)
Life Sciences & Biomedicine
(17)
Oncology
(14)
Animals
(11)
Mice
(11)
Cell Line, Tumor
(10)
Neuroblastoma
(10)
Neuroblastoma - Pathology
(8)
Cancer
(7)
Gene Expression
(7)
Tumors
(7)
Mice, Transgenic
(6)
Micrornas - Genetics
(6)
Neuroblastoma - Genetics
(6)
Cell Biology
(5)
N-Myc Proto-Oncogene Protein - Metabolism
(5)
Neuroblastoma - Metabolism
(5)
Tumorigenesis
(5)
Apoptosis
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN

Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition

MiR‐137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A

Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment

Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma

MEIS2 Is an Adrenergic Core Regulatory Transcription Factor Involved in Early Initiation of TH-MYCN-Driven Neuroblastoma Formation

MYCN-targeting miRNAs are predominantly downregulated during MYCN‑driven neuroblastoma tumor formation

Effective Alu repeat based RT-Qpcr normalization in cancer cell perturbation experiments

RNA expression signatures and posttranscriptional regulation in diabetic nephropathy

BET bromodomain protein inhibition is a therapeutic option for medulloblastoma

miR‐542‐3p exerts tumor suppressive functions in neuroblastoma by downregulating Survivin

Abstract 2481: Time-resolved transcriptome analysis of murine TH-MYCN driven neuroblastoma identifies MEIS2 as early initiating factor and novel core gene regulatory circuitry constituent

Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma

Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time

Model-Based Classification for Digital PCR: Your Umbrella for Rain

MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma

Abstract 1527: BRD3 as a specific vulnerable therapeutic target in neuroblastoma

Abstract LB-051: High LDHA expression predicts decreased survival in neuroblastoma

miRBase Tracker: keeping track of microRNA annotation changes

MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma

SP248ENDOGENOUS CONTROLS FOR MIRNA ANALYSIS IN RNEAL CELLS AND TISSUE

Targeting tachykinin receptors in neuroblastoma

Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis

Abstract 3967: BET protein inhibitor OTX015 has selective anti-tumoral activity in preclinical models of MYCN- amplified neuroblastoma

The mutational landscape of MYCN, Lin28b and ALKF1174L driven murine neuroblastoma mimics human disease

Suchergebnisse filtern